Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

A. S M Yong; J. M. Goldman

doi:10.1038/sj.bmt.1701729

Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

A. S M Yong, J. M. Goldman

Blood Cancer Program

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.

Original language	English
Pages (from-to)	827-828
Number of pages	2
Journal	Bone Marrow Transplantation
Volume	23
Issue number	8
DOIs	https://doi.org/10.1038/sj.bmt.1701729
Publication status	Published or Issued - 1999

Keywords

Bone marrow transplantation
Chronic myeloid leukaemia
Late relapse

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1701729

Link to publication in Scopus

Cite this

@article{f214bf8cf2144e64acf81f453709503c,

title = "Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation",

abstract = "Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.",

keywords = "Bone marrow transplantation, Chronic myeloid leukaemia, Late relapse",

author = "Yong, {A. S M} and Goldman, {J. M.}",

year = "1999",

doi = "10.1038/sj.bmt.1701729",

language = "English",

volume = "23",

pages = "827--828",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation

AU - Yong, A. S M

AU - Goldman, J. M.

PY - 1999

Y1 - 1999

N2 - Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.

AB - Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.

KW - Bone marrow transplantation

KW - Chronic myeloid leukaemia

KW - Late relapse

UR - http://www.scopus.com/inward/record.url?scp=0032921093&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701729

DO - 10.1038/sj.bmt.1701729

M3 - Article

C2 - 10231146

AN - SCOPUS:0032921093

VL - 23

SP - 827

EP - 828

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -